Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Causal associations between erectile dysfunction and high blood pressure, negative psychology: a Mendelian randomization study
1Department of Urology, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, 432000 Xiaogan, Hubei, China
2Department of Health Management Research Center, The First People’s Hospital of Jiangxia District, 430200 Wuhan, Hubei, China
3Department of Cardiovascular, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, 432000 Xiaogan, Hubei, China
DOI: 10.22514/jomh.2023.084 Vol.19,Issue 9,September 2023 pp.36-58
Submitted: 27 February 2023 Accepted: 11 April 2023
Published: 30 September 2023
*Corresponding Author(s): Zhuo Wei E-mail: wei_zhuo@foxmail.com
† These authors contributed equally.
Erectile dysfunction (ED) has been closely associated with both high blood pressure (HBP) and psychological traits, but the causal relationship between them remains unclear. Herein, we aimed to identify the causal risk factors for ED. We conducted univariable and multivariable Mendelian randomization (MR) analyses using genetic variants associated with metabolic syndrome and psychology traits at the genome-wide significance (p < 5 × 10−8) level obtained from corresponding genome-wide association studies. We used summary-level statistical data for ED from the European Bioinformatics Institute (EBI) database of complete Genome-Wide Association Studies (GWAS) summary data. We also conducted reverse causality and performed power calculations for MR. Our results showed that HBP was associated with increased odds of ED (odds ratio (OR) = 1.66 (95% confidence interval (CI), 1.13–2.45), a p-value for the inverse variance-weighted method (PIVW ) = 1.06 × 10−2, Power = 100%), as were myocardial infarction (OR = 1.09 (95% CI, 1.02–1.17), PIVW = 1.18 × 10−2, Power = 56%) and ischemic stroke (OR = 1.21 (95% CI, 1.02–1.43), PIVW = 2.87 × 10−2, Power = 10%). In terms of psychological traits, irritable mood (OR = 1.86 (95% CI, 1.14–3.02), PIVW = 1.30 × 10−2, Power = 96%) and neuroticism (OR = 1.36 (95% CI, 1.04–1.79), PIVW = 2.66 × 10−2, Power = 80%) were associated with increased odds of ED. Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) showed no evidence of pleiotropic bias, and sensitivity analyses confirmed the robustness of our results. We have established a causal link between HBP and ED, and we have also found evidence suggesting a causal relationship between irritable mood and ED.
Erectile dysfunction; High blood pressure; Negative psychology; Single-nucleotide polymorphisms; Mendelian randomization
Zhou Sun,Jun Hu,Yanping Luo,Hui Shu,Zheqi Fan,Songtao Shuang,Pan Lu,Bang Xiao,Zhuo Wei. Causal associations between erectile dysfunction and high blood pressure, negative psychology: a Mendelian randomization study. Journal of Men's Health. 2023. 19(9);36-58.
[1] Najari BB, Kashanian JA. Erectile dysfunction. JAMA. 2016; 316: 1838.
[2] McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. The Journal of Sexual Medicine. 2016; 13: 153–167.
[3] Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. The Journal of Urology. 1994; 151: 54–61.
[4] Baldwin K, Ginsberg P, Harkaway RC. Under-reporting of erectile dysfunction among men with unrelated urologic conditions. International Journal of Impotence Research. 2003; 15: 87–89.
[5] Irwin GM. Erectile dysfunction. Primary Care: Clinics in Office Practice. 2019; 46: 249–255.
[6] Shamloul R, Ghanem H. Erectile dysfunction. The Lancet. 2013; 381: 153–165.
[7] Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.
[8] Nobre PJ. Psychological determinants of erectile dysfunction: testing a cognitive-emotional model. The Journal of Sexual Medicine. 2010; 7: 1429–1437.
[9] Flesia L, Monaro M, Jannini EA, Limoncin E. “I’m too old for that”: the role of ageism and sexual dysfunctional beliefs in sexual health in a sample of heterosexual and LGB older adults: a pilot study. Healthcare. 2023; 11: 459.
[10] Kjaergaard AD, Marouli E, Papadopoulou A, Deloukas P, Kuś A, Sterenborg R, et al. Thyroid function, sex hormones and sexual function: a Mendelian randomization study. European Journal of Epidemiology. 2021; 36: 335–344.
[11] Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.
[12] Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009; 120: 1640–1645.
[13] Ostfeld RJ, Allen KE, Aspry K, Brandt EJ, Spitz A, Liberman J, et al. Vasculogenic erectile dysfunction: the impact of diet and lifestyle. The American Journal of Medicine. 2021; 134: 310–316.
[14] Yuan C, Jian Z, Gao X, Jin X, Wang M, Xiang L, et al. Type 2 diabetes mellitus increases risk of erectile dysfunction independent of obesity and dyslipidemia: a Mendelian randomization study. Andrology. 2022; 10: 518–524.
[15] Cordero A, Bertomeu-Martínez V, Mazón P, Fácila L, González-Juanatey JR. Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. Postgraduate Medicine. 2010; 122: 51–56.
[16] Kratz MT, Schumacher H, Sliwa K, Schmieder R, Pöss J, Mahfoud F, et al. Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. European Journal of Preventive Cardiology. 2014; 21: 272–280.
[17] Sanchez E, Pastuszak AW, Khera M. Erectile dysfunction, metabolic syn-drome, and cardiovascular risks: facts and controversies. Translational Andrology and Urology. 2017; 6: 28–36.
[18] Heruti R, Shochat T, Tekes‐Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: results of a large‐scale survey. The Journal of Sexual Medicine. 2004; 1: 284–291.
[19] Seligman ME, Steen TA, Park N, Peterson C. Positive psychology progress: empirical validation of interventions. American Psychologist. 2005; 60: 410–21.
[20] Orimoloye OA, Feldman DI, Blaha MJ. Erectile dysfunction links to cardiovascular disease—defining the clinical value. Trends in Cardiovas-cular Medicine. 2019; 29: 458–465.
[21] Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. 2016; 167: 1415–1429.e19.
[22] Nagel M, Watanabe K, Stringer S, Posthuma D, van der Sluis S. Item-level analyses reveal genetic heterogeneity in neuroticism. Nature Communications. 2018; 9: 905.
[23] de Moor MHM, Costa PT, Terracciano A, Krueger RF, de Geus EJC, Toshiko T, et al. Meta-analysis of genome-wide association studies for personality. Molecular Psychiatry. 2012; 17: 337–349.
[24] Okbay A, Baselmans BM, De Neve JE, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nature Genetics. 2016; 48: 624–33.
[25] Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics. 2018; 50: 524–37.
[26] Hartiala JA, Han Y, Jia Q, Hilser JR, Huang P, Gukasyan J, et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. European Heart Journal. 2021; 42: 919–33.
[27] Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics. 2018; 50: 1412–25.
[28] Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nature Genetics. 2019; 51: 237–44.
[29] Bovijn J, Jackson L, Censin J, Chen CY, Laisk T, Laber S, et al. GWAS identifies risk locus for erectile dysfunction and implicates hypothalamic neurobiology and diabetes in etiology. The American Journal of Human Genetics. 2019; 104: 157–63.
[30] Burgess S, Thompson SG. Mendelian Randomization: Methods for Causal Inference Using Genetic Variants. 2nd edn. Chapman and Hall/CRC: New York. 2015.
[31] Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. International Journal of Epidemiology. 2016; 45: 1961–74.
[32] Grover S, Lill CM, Kasten M, Klein C, Del Greco MF, Konig IR. Risky behaviors and Parkinson disease: a Mendelian randomization study. Neurology. 2019; 93: e1412–e24.
[33] Shi X, Yuan W, Cao Q, Cui W. Education plays a crucial role in the pathway from poverty to smoking: a Mendelian randomization study. Addiction. 2023; 118: 128–139.
[34] Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genetic Epidemiology. 2016; 40: 304–314.
[35] Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology. 2015; 44: 512–525.
[36] Verbanck M, Chen C, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics. 2018; 50: 693–698.
[37] Zhu H, Zhou X. Statistical methods for SNP heritability estimation and partition: a review. Computational and Structural Biotechnology Journal. 2020; 18: 1557–1568.
[38] Brion MA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology. 2013; 42: 1497–1501.
[39] Burgess S. Sample size and power calculations in Mendelian ran-domization with a single instrumental variable and a binary outcome. International Journal of Epidemiology. 2014; 43: 922–929.
[40] Sarma AV, Hotaling JM, de Boer IH, Dunn RL, Oerline MK, Singh K, et al. Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes. Journal of Hypertension. 2019; 37: 1070–1076.
[41] Hsiao W, Bertsch RA, Hung Y, Aaronson DS. Tighter blood pressure control is associated with lower incidence of erectile dysfunction in hypertensive men. The Journal of Sexual Medicine. 2019; 16: 410–417.
[42] de Oliveira AA, Nunes KP. Hypertension and erectile dysfunction: breaking down the challenges. American Journal of Hypertension. 2021; 34: 134–142.
[43] Karpova T, de Oliveira AA, Naas H, Priviero F, Nunes KP. Blockade of toll-like receptor 4 (TLR4) reduces oxidative stress and restores phospho-ERK1/2 levels in Leydig cells exposed to high glucose. Life Sciences. 2020; 245: 117365.
[44] Nunes KP, Oliveira AA, Mowry FE, Biancardi VC. Targeting toll‐like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension? British Journal of Pharmacology. 2019; 176: 1864–1879.
[45] Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The in terplay between angiotensin II, TLR4 and hypertension. Pharmacological Research. 2017; 120: 88–96.
[46] Nunes KP, Bomfim GF, Toque HA, Szasz T, Clinton Webb R. Toll-like receptor 4 (TLR4) impairs nitric oxide contributing to angiotensin II-induced cavernosal dysfunction. Life Sciences. 2017; 191: 219–226.
[47] Bomfim GF, Echem C, Martins CB, Costa TJ, Sartoretto SM, Dos Santos RA, et al. Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sciences. 2015; 122: 1–7.
[48] Carneiro FS, Zemse S, Giachini FR, Carneiro ZN, Lima VV, Webb RC, et al. TNF-alpha infusion impairs corpora cavernosa reactivity. The Journal of Sexual Medicine. 2009; 6: 311–9.
[49] Bomfim G, Santos RD, Oliveira M, Giachini F, Akamine E, Tostes R, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clinical Science. 2012; 122: 535–543.
[50] Carneiro FS, Sturgis LC, Giachini FR, Carneiro ZN, Lima VV, Wynne BM, et al. TNF-alpha knockout mice have increased corpora cavernosa relaxation. The Journal of Sexual Medicine. 2009; 6: 115–25.
[51] Koehn J, Crodel C, Deutsch M, Kolominsky-Rabas PL, Hösl KM, Köhrmann M, et al. Erectile dysfunction (ED) after ischemic stroke: association between prevalence and site of lesion. Clinical Autonomic Research. 2015; 25: 357–365.
[52] Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. European Urology. 2007; 52: 1590–1600.
[53] Dhanesha N, Patel RB, Doddapattar P, Ghatge M, Flora GD, Jain M, et al. PKM2 promotes neutrophil activation and cerebral thromboinflam-mation: therapeutic implications for ischemic stroke. Blood. 2022; 139: 1234–1245.
[54] Thackeray JT, Hupe HC, Wang Y, Bankstahl JP, Berding G, Ross TL, et al. Myocardial inflammation predicts remodeling and neuroinflammation after myocardial infarction. Journal of the American College of Cardiology. 2018; 71: 263–275.
[55] Lee S, Lee C, Kang S, Park I, Kim YH, Kim SK, et al. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction. Journal of Clinical Investigation. 2018; 128: 5018–5033.
[56] Tomada N, Tomada I, Botelho F, Pacheco-Figueiredo L, Lopes T, Negrão R, et al. Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of Angiopoietin imbalance? Andrology. 2013; 1: 541–548.
[57] Winder K, Seifert F, Köhrmann M, Crodel C, Kloska S, Dörfler A, et al. Lesion mapping of stroke-related erectile dysfunction. Brain. 2017; 140: 1706–1717.
[58] Ackerman MD, Carey MP. Psychology’s role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Journal of Consulting and Clinical Psychology. 1995; 63: 862–76.
[59] Moore TM, Strauss JL, Herman S, Donatucci CF. Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. Journal of Sex & Marital Therapy. 2003; 29: 381–399.
[60] Chen WK, Zhou T, Yu DD, Li JP, Wu JG, Li LJ, et al. Effects of major depression and bipolar disorder on erectile dysfunction: a two-sample mendelian randomization study. BMC Medical Genomics. 2023; 16: 66.
[61] Ma K, Song P, Liu Z, Yang L, Wang L, Zhou J, et al. Genetic evidence suggests that depression increases the risk of erectile dysfunction: a Mendelian randomization study. Frontiers in Genetics. 2022; 13: 1026227.
[62] Brotman MA, Kircanski K, Stringaris A, Pine DS, Leibenluft E. Irritability in youths: a translational model. American Journal of Psychiatry. 2017; 174: 520–532.
[63] Snaith RP, Taylor CM. Irritability: definition, assessment and associated factors. British Journal of Psychiatry. 1985; 147: 127–136.
[64] Vidal-Ribas P, Stringaris A. How and why are irritability and depression linked? Child and Adolescent Psychiatric Clinics of North America. 2021; 30: 401–414.
[65] Kesebir S, Erdinç B, Tarhan N. Predictors of metabolic syndrome in first manic episode. Asian Journal of Psychiatry. 2017; 25: 179–183.
[66] Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. The American Journal of Cardiology. 2000; 86: 41–45.
[67] Aihara M, Ida I, Yuuki N, Oshima A, Kumano H, Takahashi K, et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Research: Neuroimaging. 2007; 155: 245–256.
[68] Perugi G, Quaranta G, Belletti S, Casalini F, Mosti N, Toni C, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. Journal of Affective Disorders. 2015; 170: 95–103.
[69] Filippi S. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Molecular Human Reproduction. 2003; 9: 765–774.
[70] Koca O, Çalışkan S, Öztürk Mİ, Güneş M, Kılıçoğlu G, Karaman MI. Vasculogenic erectile dysfunction and metabolic syndrome. The Journal of Sexual Medicine. 2010; 7: 3997–4002.
[71] Lee Y, Liu C, Huang C, Li W, Wu W, Yeh H, et al. The potential impact of metabolic syndrome on erectile dysfunction in aging taiwanese males. The Journal of Sexual Medicine. 2010; 7: 3127–3134.
[72] Huang PL. A comprehensive definition for metabolic syndrome. Disease Models & Mechanisms. 2009; 2: 231–237.
[73] Ma J, Zhang Y, Bao B, Chen W, Li H, Wang B. Prevalence and associated factors of erectile dysfunction, psychological disorders, and sexual performance in primary vs. secondary infertility men. Reproductive Biology and Endocrinology. 2021; 19: 43.
[74] Quinta Gomes AL, Nobre P. Personality traits and psychopathology on male sexual dysfunction: an empirical study. The Journal of Sexual Medicine. 2011; 8: 461–469.
[75] Crafa A, Condorelli RA, Mongioi LM, Cannarella R, Barbagallo F, Aversa A, et al. Mean platelet volume as a marker of vasculogenic erectile dysfunction and future cardiovascular risk. Journal of Clinical Medicine. 2020; 9: 2513.
[76] Aldemir M, Akdemir F, Okulu E, Ener K, Ozayar A, Gudeloglu A. Evaluation of blood platelet count and function in patients with erectile dysfunction. Andrologia. 2016; 48: 189–192.
[77] Millett C. Smoking and erectile dysfunction: findings from a representa-tive sample of Australian men. Tobacco Control. 2006; 15: 136–139.
[78] Mykoniatis I, Grammatikopoulou MG, Bouras E, Karampasi E, Tsionga A, Kogias A, et al. Sexual dysfunction among young men: overview of dietary components associated with erectile dysfunction. The Journal of Sexual Medicine. 2018; 15: 176–182.
[79] Lopez DS, Liu L, Rimm EB, Tsilidis KK, de Oliveira Otto M, Wang R, et al. Coffee intake and incidence of erectile dysfunction. American Journal of Epidemiology. 2018; 187: 951–9.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)
Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.
Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).
Top